Skip to main content
Vaishalee Kenkre, MD, Oncology, Madison, WI

Vaishalee Padgaonkar Kenkre MD

Hematologic Oncology


Associate Professor, Medicine, University of Wisconsin Medical School

Join to View Full Profile
  • 600 Highland AveMadison, WI 53792

  • Phone+1 608-265-1700

Dr. Kenkre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 2004 - 2007
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 2004

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2010 - 2025
  • IL State Medical License
    IL State Medical License 2007 - 2014
  • Hematology
    American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Vaishalee P. Kenkre, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • UW Study Provides Potential Treatment Strategy for Aggressive Lymphoma
    UW Study Provides Potential Treatment Strategy for Aggressive LymphomaJune 12th, 2019

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: